Docetaxel

Generic Name
Docetaxel
Brand Names
Taxotere, Docetaxel Accord, Docetaxel Kabi
Drug Type
Small Molecule
Chemical Formula
C43H53NO14
CAS Number
114977-28-5
Unique Ingredient Identifier
699121PHCA
Background

Docetaxel is a clinically well established anti-mitotic chemotherapy medication used for the treatment of different types of cancer, including breast, ovarian, and non-small cell lung cancer. Docetaxel is a complex diterpenoid molecule and a semisynthetic analogue of paclitaxel. Docetaxel reversibly binds to microtubulin with high affinity in a 1:1 stoichiom...

Indication

Docetaxel is indicated as a single agent for the treatment of locally advanced or metastatic breast cancer after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC. It is also indicated as a single agent for locally advanced or metastatic non-small cell lung cancer (NSCLC) after platinum therapy...

Associated Conditions
Esophageal Cancer, Ewing's Sarcoma, Locally Advanced Breast Cancer (LABC), Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), Node Positive Breast Cancer, Ovarian Cancer Metastatic, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Advanced untreated gastric adenocarcinoma, Locally advanced Squamous cell carcinoma of head and neck, Locally advanced untreated non small cell lung cancer, Metastatic untreated non small cell lung cancer, Refractory, locally advanced Non small cell lung cancer, Refractory, metastatic Non small cell lung cancer, Refractory, metastatic hormone-refractory Prostate cancer
Associated Therapies
-
Clinical Trials
Related News

A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer

First Posted Date
2023-08-25
Last Posted Date
2024-12-19
Lead Sponsor
Seagen Inc.
Target Recruit Count
600
Registration Number
NCT06012435
Locations
🇨🇭

Inselspital, Bern, Other, Switzerland

🇫🇷

Hospital Center De Cornouaille, Quimper Cedex, Other, France

🇫🇷

Centre Hospitalier Universitaire de Rennes, Hopital Pontchaillou, Rennes, Other, France

and more 135 locations

A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer

First Posted Date
2023-08-21
Last Posted Date
2024-12-06
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
105
Registration Number
NCT05999994
Locations
🇧🇪

UCL- Saint Luc, Bruxelles, Belgium

🇫🇷

Institut Curie, Paris, France

🇳🇱

Prinses Maxima Centrum, Utrecht, Netherlands

and more 63 locations

Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC

First Posted Date
2023-08-09
Last Posted Date
2023-08-09
Lead Sponsor
The First Affiliated Hospital with Nanjing Medical University
Target Recruit Count
200
Registration Number
NCT05983783
Locations
🇨🇳

Urology dpt, First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China

Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy

First Posted Date
2023-08-07
Last Posted Date
2023-11-30
Lead Sponsor
wang shusen
Target Recruit Count
116
Registration Number
NCT05978648
Locations
🇨🇳

Sun-yat sen university cancer center, Guangzhou, Gangdong, China

Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

First Posted Date
2023-07-27
Last Posted Date
2023-11-18
Lead Sponsor
Akeso
Target Recruit Count
90
Registration Number
NCT05960955
Locations
🇨🇳

Tianjin Provincial Tumor Hospital, Tianjin, China

A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma

First Posted Date
2023-07-13
Last Posted Date
2024-07-18
Lead Sponsor
Sichuan Baili Pharmaceutical Co., Ltd.
Target Recruit Count
584
Registration Number
NCT05943795
Locations
🇨🇳

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

First Posted Date
2023-07-03
Last Posted Date
2024-10-31
Lead Sponsor
SWOG Cancer Research Network
Target Recruit Count
2400
Registration Number
NCT05929768
Locations
🇺🇸

Northwestern Medicine Cancer Center Warrenville, Warrenville, Illinois, United States

🇺🇸

Cedars Sinai Medical Center, Los Angeles, California, United States

🇺🇸

Cancer Center of Kansas-Independence, Independence, Kansas, United States

and more 427 locations

Pembrolizumab in Locally Advanced Sinonasal Carcinoma

First Posted Date
2023-06-29
Last Posted Date
2024-12-18
Lead Sponsor
Istituti Clinici Scientifici Maugeri SpA
Target Recruit Count
28
Registration Number
NCT05925491
Locations
🇮🇹

Istituti Clinici Scientifici Maugeri, Pavia, Lombardia, Italy

Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation

First Posted Date
2023-06-26
Last Posted Date
2024-01-24
Lead Sponsor
Hummingbird Bioscience
Target Recruit Count
68
Registration Number
NCT05919537
Locations
🇦🇺

ICON Cancer Centre South Brisbane, Brisbane, Queensland, Australia

🇦🇺

GenesisCare North Shore, Sydney, New South Wales, Australia

🇦🇺

Southern Oncology Clinical Research Unit, Adelaide, South Australia, Australia

and more 2 locations

Study of an Anti-HER3 Antibody, HMBD-001, With Docetaxel +/- Cetuximab in Advanced Squamous Non-small Cell Lung Cancers, and HMBD-001 + Cetuximab in Advanced Squamous Cell Cancers

First Posted Date
2023-06-20
Last Posted Date
2024-10-23
Lead Sponsor
Hummingbird Bioscience
Target Recruit Count
98
Registration Number
NCT05910827
Locations
🇲🇩

The Institute of Oncology, ARENSIA Exploratory Medicine Phase I Unit, Chisinau, Moldova, Republic of

🇦🇺

GenesisCare North Shore, Sydney, New South Wales, Australia

🇦🇺

ICON Cancer Centre South Brisbane, Brisbane, Queensland, Australia

and more 6 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy